AQST

Today, 4:30 AMAquestive Therapeutics Inc is scheduled to announce earnings today after market close

Peers: SPRY INDV AMPH XERS EBS VTRS AMRX SUPN ZVRA LPCN

| Held by: VTI IWM VXF XPH VTWO IWN IWO IWC FSCC SURI

Index	RUT
Market Cap	485.93M
Enterprise Value	536.53M
Income	-78.23M
Sales	54.09M
Book/sh	-0.45
Cash/sh	0.78
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	147
IPO	Jul 25, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	8.98
P/B	-
P/C	4.93
P/FCF	-
EV/EBITDA	-
EV/Sales	9.92
Quick Ratio	6.74
Current Ratio	7.19
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-0.65
EPS next Y	-0.50
EPS next Q	-0.12
EPS this Y	37.75%
EPS next Y	-2.97%
EPS next 5Y	21.87%
EPS past 3/5Y	11.13% 13.92%
Sales past 3/5Y	-2.24% -0.58%
EPS Y/Y TTM	5.86%
Sales Y/Y TTM	22.56%
EPS Q/Q	-34.09%
Sales Q/Q	38.15%
Earnings	Nov 03 AMC
EPS/Sales Surpr.	-71.43% 21.03%

Insider Own	12.46%
Insider Trans	-1.06%
Inst Own	47.31%
Inst Trans	-1.50%
ROA	-69.29%
ROE	-
ROIC	-86.35%
Gross Margin	67.04%
Oper. Margin	-97.52%
Profit Margin	-144.63%
SMA20	-7.84%
SMA50	-16.25%
SMA200	-8.11%
Trades

Shs Outstand	125.51M
Shs Float	109.87M
Short Float	25.12%
Short Ratio	10.09
Short Interest	27.60M
52W High	6.85 -43.48%
52W Low	2.93 32.14%
Volatility	6.19% 5.65%
ATR (14)	0.23
RSI (14)	38.74
Beta	1.51
Rel Volume	0.45
Avg Volume	2.74M
Volume	254,691

Perf Week	-4.87%
Perf Month	-15.28%
Perf Quarter	3.11%
Perf Half Y	-7.38%
Perf YTD	-40.07%
Perf Year	-40.35%
Perf 3Y	141.97%
Perf 5Y	-34.38%
Perf 10Y	-
Recom	1.00
Target Price	9.33
Prev Close	3.77
Price	3.87
Change %	2.69%

Consensus

Strong Buy

Avg. Price Target

$9.33

Implied Upside

+141.0%

Analysts9incl. previous ratings

Rating Distribution9 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Apr 24, 2026	Resumed	OOppenheimer	Outperform	$8	+106.6%
Jun 02, 2025	Resumed	OOppenheimer	Outperform	$7	+80.8%
Dec 17, 2024	Initiated	CCantor Fitzgerald	Overweight	$17	+339.1%
May 10, 2024	Initiated	LLeerink Partners	Outperform	$8	+106.6%
Apr 11, 2024	Initiated	PPiper Sandler	Overweight	$10	+158.3%
Mar 28, 2024	Initiated	RRaymond James	Outperform	$7	+80.8%
Apr 07, 2021	Resumed	RRBC Capital Mkts	Outperform	$7	+80.8%
Apr 22, 2019	Initiated	HH.C. Wainwright	Buy
Jan 03, 2019	Initiated	LLake Street	Buy	$14	+261.6%
Aug 20, 2018	Initiated	RRBC Capital Mkts	Outperform	$23	+494.1%
Aug 20, 2018	Initiated	JJMP Securities	Mkt Outperform	$29	+649.0%

Oct-27-26 12:53PM	Aquestive's Q3 Report Hinges On Anafilm Resubmission Proof As Revenue Expected To Cool (Earnings Whispers)
07:00AM	Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET (GlobeNewswire)
Oct-15-26 07:00AM	Aquestive Therapeutics Announces FDA Acceptance of Anaphylm NDA Resubmission and PDUFA Goal Date of March 16, 2027 (GlobeNewswire) -11.93%
Sep-29-26 07:00AM	Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly (GlobeNewswire)
Sep-17-26 07:00AM	Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm (dibutepinephrine) Sublingual Film (GlobeNewswire)
07:00AM	Loading…
Sep-01-26 07:00AM	Aquestive Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-12-26 07:04PM	Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ... (GuruFocus.com)
Aug-11-26 04:22PM	Aquestive Therapeutics: Q2 Earnings Snapshot (Associated Press)
04:01PM	Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
09:21AM	Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 40% Downside (GuruFocus.com)
Aug-10-26 10:24AM	Aquestive Therapeutics shares jump after encouraging Anaphylm study results (InvestorsHub) +8.88%
09:20AM	Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 35% Downside (GuruFocus.com)
07:00AM	Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm (dibutepinephrine) Sublingual Film (GlobeNewswire)
Jul-29-26 07:00AM	Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET (GlobeNewswire)
Jul-07-26 07:00AM	Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
03:00AM	Loading…
Jun-23-26 03:00AM	Does US manufacturing give drugmakers a speed edge? (Pharma Voice) +6.57%
May-14-26 07:03PM	Aquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com) +14.53% -11.84%
May-13-26 04:10PM	Aquestive Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:01PM	Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-12-26 09:31AM	Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree (GlobeNewswire)
May-06-26 07:00AM	Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET (GlobeNewswire)
Mar-30-26 07:00AM	Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm (dibutepinephrine) Sublingual Film (GlobeNewswire)
Mar-26-26 09:00AM	AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt (PR Newswire)
Mar-20-26 07:00AM	Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer (GlobeNewswire)
Mar-12-26 09:00AM	AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt (PR Newswire) -5.62%
Mar-09-26 04:01PM	Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-26 06:47PM	Aquestive Therapeutics Q4 Earnings Call Highlights (MarketBeat)
02:01PM	Aquestive Therapeutics Inc (AQST) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Legal ... (GuruFocus.com)
Mar-04-26 06:30PM	Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics (Zacks) +6.07%
05:15PM	Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:25PM	Loading…
04:25PM	Aquestive Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
07:20AM	Aquestive Therapeutics Inc (AQST) Q4 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
Mar-03-26 07:19AM	Aquestive Therapeutics Inc (AQST) Q4 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Mar-02-26 06:00PM	Harrow (HROW) Misses Q4 Earnings Estimates (Zacks) +5.25%
Feb-26-26 03:48PM	Aquestive Therapeutics Touts Anaphylm, Targets Q3 FDA Resubmission After CRL at Oppenheimer Conference (MarketBeat)
Feb-25-26 07:00AM	Aquestive Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-24-26 07:00AM	Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET (GlobeNewswire)
Feb-23-26 04:33PM	Lake Street Adjusts Aquestive Therapeutics, Inc. (AQST) Valuation Model on Expected Approval Delay (Insider Monkey)
07:00AM	Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-20-26 07:00AM	Aquestive Therapeutics to Present New Clinical Data on Anaphylm (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting (GlobeNewswire)
Feb-18-26 07:00AM	Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer (GlobeNewswire)
Feb-04-26 08:46AM	Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street (TipRanks)
Feb-03-26 10:45AM	Leerink sees silver lining in Aquestive CRL given defined path to approval (TipRanks)
05:50AM	Aquestive receives FDA CRL for Anaphylm allergic reaction treatment (Pharmaceutical Technology)
Feb-02-26 05:17PM	Health Care Roundup: Market Talk (The Wall Street Journal) +38.98%
01:12PM	What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment? (Benzinga)
12:52PM	Aquestive Therapeutics Gets FDA CRL for Anaphylm, Eyes Q3 Resubmission After Human Factors Fixes (MarketBeat)
07:00AM	Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm (GlobeNewswire)
Jan-22-26 03:09AM	Jim Cramer on Aquestive Therapeutics: "I'm Not Sure If They Deserve the Benefit of the Doubt" (Insider Monkey)
Jan-14-26 09:55AM	Here's Why Aquestive Therapeutics (AQST) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jan-12-26 09:09PM	Lightning Round: Sony is a buy here, says Jim Cramer (CNBC TV) -10.23%
09:35AM	Down 37% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround (Zacks)
Jan-10-26 09:00AM	Morning Movers: Oklo, Vistra climb following Meta nuclear energy deals (TipRanks)
Jan-09-26 12:32PM	Bad News For Competitor Turns Into Big Win For ARS Pharma Stock (Benzinga) -37.04%
11:28AM	Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application (Benzinga)
07:00AM	Aquestive Therapeutics Announces Regulatory Development for Anaphylm (dibutepinephrine) Sublingual Film and Provides Business Update (GlobeNewswire)
Jan-07-26 12:00PM	Aquestive Therapeutics (AQST) Upgraded to Buy: Here's Why (Zacks)
Nov-24-25 07:00AM	Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 12:09PM	Jim Cramer on Aquestive Therapeutics: "I Think It's a Very Interesting Spec" (Insider Monkey) -5.02%
Nov-11-25 08:35PM	Lightning Round: Joby Aviation is losing too much money, says Jim Cramer (CNBC TV)
Nov-06-25 02:09PM	Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com)
Nov-05-25 06:00PM	Here's What Key Metrics Tell Us About Aquestive Therapeutics (AQST) Q3 Earnings (Zacks)
05:35PM	Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:37PM	Aquestive Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
07:44AM	Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-04-25 08:14AM	Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com) -6.32%
07:00AM	Aquestive Therapeutics Announces Leadership Expansion to Support Growth (GlobeNewswire)
Nov-03-25 07:00AM	Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler (GlobeNewswire)
Oct-31-25 09:40AM	Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-30-25 07:00AM	Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting (GlobeNewswire)
Oct-27-25 07:00AM	Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET (GlobeNewswire)
Oct-15-25 09:40AM	Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year? (Zacks) +6.69%
Oct-10-25 08:59AM	Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains? (Zacks)
Oct-08-25 07:00AM	Aquestive Therapeutics Broadens Patent Estate for Anaphylm (GlobeNewswire)
Sep-22-25 04:37AM	Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock? (Zacks) -8.82%
03:42AM	Jim Cramer on Aquestive Therapeutics: "I think it's Worth Taking a Chance On" (Insider Monkey)
Sep-05-25 11:00AM	AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA (Zacks) +7.11%
Sep-04-25 12:44PM	FDA Confirms Direct Review Path For Aquestive's Allergy Treatment (Benzinga) +28.10%
07:00AM	Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm (GlobeNewswire)
Aug-26-25 07:00AM	Aquestive Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-18-25 06:57AM	Aquestive signs $75m agreement for launch of Anaphylm (Pharmaceutical Technology)
Aug-14-25 09:40AM	Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? (Zacks)
06:28AM	Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock (GlobeNewswire)
06:00AM	Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Aug-11-25 07:30PM	Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics (Zacks)
06:55PM	Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:07PM	Aquestive Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
09:32AM	Aquestive Therapeutics Inc (AQST) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-08-25 09:25AM	Aquestive Therapeutics Inc (AQST) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-04-25 07:00AM	Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET (GlobeNewswire) +5.24%
Jul-22-25 05:20PM	USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates (Zacks) -6.15% +7.30%
07:00AM	Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer (GlobeNewswire)
Jul-15-25 07:00AM	Aquestive Therapeutics Provides International Expansion Update for Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Jul-07-25 07:00AM	Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
Jul-02-25 10:06PM	H.C. Wainwright Reaffirms Buy on Aquestive Therapeutics, Inc. (AQST) After FDA Approval (Insider Monkey) +8.24%
Jun-25-25 07:00AM	Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit (GlobeNewswire)
Jun-24-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barber Daniel	President and CEO	Oct 15 '26	Sale	4.22	25,000	105,600	627,317	Oct 16 02:17 PM
Barber Daniel	President and CEO	Sep 15 '26	Sale	4.82	25,000	120,487	652,317	Sep 16 02:00 PM
Daniel Barber	Director	Sep 15 '26	Proposed Sale	4.88	50,000	244,000		Sep 15 04:48 PM
Korczynski Sherry	Chief Commercial Officer	Sep 09 '26	Option Exercise	2.65	8,750	23,188	244,439	Sep 11 11:07 AM
Korczynski Sherry	Chief Commercial Officer	Sep 09 '26	Sale	5.22	8,750	45,675	235,689	Sep 11 11:07 AM
Sherry M. Korczynski	Officer	Sep 09 '26	Proposed Sale	5.21	8,750	45,588		Sep 09 04:20 PM
Barber Daniel	President and CEO	Aug 17 '26	Sale	4.29	25,000	107,168	585,574	Aug 18 04:13 PM
Daniel Barber	Officer	Aug 17 '26	Proposed Sale	4.25	25,000	106,250		Aug 17 04:34 PM
Barber Daniel	President and CEO	Jul 16 '26	Sale	4.00	20,369	81,509	610,574	Jul 17 01:15 PM
Barber Daniel	President and CEO	Jul 15 '26	Sale	4.03	4,631	18,683	630,943	Jul 17 01:15 PM
Daniel Barber	Officer	Jul 15 '26	Proposed Sale	4.04	25,000	101,000		Jul 15 04:37 PM
Krop Julie	Director	Jun 23 '26	Option Exercise	0.71	25,000	17,830	25,000	Jun 24 11:11 AM
Krop Julie	Director	Jun 23 '26	Sale	5.02	25,000	125,392	0	Jun 24 11:11 AM
JULIE KROP	Director	Jun 23 '26	Proposed Sale	4.72	25,000	118,000		Jun 23 04:26 PM
Barber Daniel	President and CEO	Jun 15 '26	Sale	4.16	25,000	104,010	635,574	Jun 16 04:09 PM
Daniel Barber	Officer	Jun 15 '26	Proposed Sale	4.17	25,000	104,250		Jun 15 04:38 PM
Barber Daniel	President and CEO	May 15 '26	Sale	4.29	8,257	35,413	660,574	May 18 02:03 PM
Daniel Barber	Officer	May 15 '26	Proposed Sale	4.73	8,257	39,056		May 15 04:32 PM
Boyd Peter E.	Chief People Officer	Mar 10 '26	Sale	4.17	29,814	124,414	338,509	Mar 11 12:52 PM
Barber Daniel	President and CEO	Mar 10 '26	Sale	4.17	180,677	753,965	1,004,753	Mar 11 12:52 PM
BRAENDER LORI J	Chief Legal Officer	Mar 10 '26	Sale	4.17	40,102	167,346	442,879	Mar 11 12:52 PM
Cioffi Melina	SVP, Regulatory Affairs	Mar 10 '26	Sale	4.17	25,311	105,623	274,867	Mar 11 12:52 PM
TOTH A ERNEST JR	Chief Financial Officer	Mar 10 '26	Sale	4.17	58,254	243,094	376,112	Mar 11 12:51 PM
Korczynski Sherry	Chief Commercial Officer	Mar 10 '26	Sale	4.17	15,741	65,687	241,117	Mar 11 12:51 PM
Jung Cassie	Chief Operating Officer	Mar 10 '26	Sale	4.17	45,791	191,086	274,980	Mar 11 12:50 PM
Carl N. Kraus	Affiliate	Nov 17 '25	Proposed Sale	5.39	53,100	286,209		Nov 17 04:39 PM

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients' therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

CEOMr. Daniel Barber

Senior VP & CFOMr. A. Ernest Toth Jr.

Esq.Ms. Lori J. Braender BSBA

Chief Operating OfficerMs. Cassie Jung

Chief Legal Officer & Chief Compliance OfficerMr. Thomas A. Zalewski

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Aquestive Therapeutics Inc

Upgrade your Finviz experience